Antihyperlipidemic properties of beta-pyridylcarbinol. A review of preclinical studies.
The available preclinical literature on the antihyperlipidemic properties of beta-pyridylcarbinol is reviewed. Similarities between the pharmacological profiles for beta-pyridylcarbinol and nicotinic acid, and evidence for the metabolic conversion of beta-pyridylcarbinol to nicotinic acid are discussed. Several reviews discussing the antihyperlipidemic effects of beta-pyridylcarbinol (beta-PC, nicotinyl alcohol, Roniacol) and nicotinic acid (NA) have appeared during the last 15 years (1-6). However, continuing clinical interest in the ability of nicotinic acid analogs to reduce plasma lipids indicated that an update and critical evaluation of the preclinical literature on this subject would be of value in order to permit a more complete assessment of the relevance of several animal models to effects in human subjects. The literature reviewed included (a) preclinical studies of beta-PC where it was the sole compound examined; (b) comparative studies of beta-PC and NA; and (c) studies relating to the metabolism of beta-PC. The literature chosen included experiments involving fasted animals, satiated animals, and effects of Triton-induced hyperlipidemia. Data on other pharmacological properties of beta-PC and/or NA that might contribute to antihyperlipidemic efficacy (e.g., fibrinolysis, inhibition of platelet aggregation, erythrocyte membrane changes) were also included where available.
D000273:Adipose Tissue / Q000378:metabolism; D000302:Adrenal Cortex / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003327:Coronary Disease / Q000188:drug therapy; D003345:Corticosterone / Q000097:blood; D004036:Diet, Atherogenic; D004907:Erythrocyte Deformability / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005342:Fibrinolysis / Q000187:drug effects; D005508:Food Deprivation; D005990:Glycerol / Q000378:metabolism; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D007657:Ketone Bodies / Q000096:biosynthesis; D007700:Kinetics; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008862:Microsomes, Liver / Q000378:metabolism; D009132:Muscles / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D009525:Niacin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D009540:Nicotinyl Alcohol / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D010743:Phospholipids / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D014280:Triglycerides / Q000097:blood / Q000378:metabolism; D014508:Urea / Q000097:blood
D001786:Blood Glucose; D002791:Cholesterol, Dietary; D005227:Fatty Acids; D005230:Fatty Acids, Nonesterified; D007657:Ketone Bodies; D008055:Lipids; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010743:Phospholipids; D014280:Triglycerides; D009243:NAD; D009525:Niacin; D014508:Urea; D002784:Cholesterol; D009540:Nicotinyl Alcohol; D005990:Glycerol; D003345:Corticosterone